secwatch.observer — SEC 8-K summary
======================================

Issuer:     NIKA PHARMACEUTICALS, INC (NIKA)
CIK:        0001145604
Form:       8-K
Filed at:   2022-04-12T23:59:59+00:00
Accession:  0001826466-22-000034
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.01, 3.03, 5.06
LLM model:  deepseek-v4-flash:cloud@v2

Centennial Growth Equities acquires exclusive rights to TNG and supplements, exits shell status
--------------------------------------------------------------------------------

- Acquired 15-year exclusive rights to manufacture and distribute Thymus Nuclear Glycoprotein (TNG) from VITAL FE.
- Also acquired 15-year rights to dietary supplements Palmcarotilen and Fiziolong from MICAR 11.
- Consideration: 8M preferred shares (to Dimitar Savov) for TNG rights; 2M preferred shares for supplement rights.
- Preferred shares granted 1,000 votes each, giving Savov ~10B votes; company no longer a shell company.
- Dimitar Savov is CEO/Director and is the owner of both VITAL (70%) and MICAR (100%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1145604/000182646622000034/0001826466-22-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1145604/000182646622000034/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001826466-22-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer